Drug-induced lupus erythematosus historical perspective: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
==Historical Perspective== | ==Historical Perspective== | ||
Hydralazine was the first agent to be associated with the development of lupus-like symptoms in 1954. Since then, more than 100 drugs have been identified as the cause of drug-induced lupus, with the list expanding with the development of newer biologic agents each year. | |||
==References== | ==References== | ||
Revision as of 08:35, 16 November 2021
|
Drug-induced lupus erythematosus Microchapters |
|
Differentiating Drug-induced lupus erythematosus from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Drug-induced lupus erythematosus historical perspective On the Web |
|
American Roentgen Ray Society Images of Drug-induced lupus erythematosus historical perspective |
|
FDA on Drug-induced lupus erythematosus historical perspective |
|
CDC on Drug-induced lupus erythematosus historical perspective |
|
Drug-induced lupus erythematosus historical perspective in the news |
|
Blogs on Drug-induced lupus erythematosus historical perspective |
|
Directions to Hospitals Treating Drug-induced lupus erythematosus |
|
Risk calculators and risk factors for Drug-induced lupus erythematosus historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
Hydralazine was the first agent to be associated with the development of lupus-like symptoms in 1954. Since then, more than 100 drugs have been identified as the cause of drug-induced lupus, with the list expanding with the development of newer biologic agents each year.